Drug Discovery News talked with Paul Grayson, Bird Rock Bio’s president and CEO, about development of therapeutic antibody RYI-018 and their recent deal with Janssen Pharmaceuticals and GE Healthcare.
RYI-018 is unique in that antibody that stabilizes the cannabinoid 1 (CB1) receptor in an inactive conformation. Increases in CB1 activity have been indicated in progression of fibrotic and metabolic liver diseases. RYI-018 is being developed to target this increased activity and treat large unmet medical needs in diseases such as non-alcoholic steatohepatitis (NASH) and diabetic nephropathy.
Under the recent agreement, Janssen received an exclusive option to acquire Bird Rock following a Phase 1 data readout. Furthermore, GE Healthcare has agreed to partner with Bird Rock for process development, formulation, and manufacturing of RYI-018 in preparation for Phase 2 studies.
Read the full story at Drug Discovery News.
More details on the partnerships and RYI-018 in our recent press release.